

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 39/395, C07K 16/00, C12Q 1/70	A1	(11) International Publication Number: WO 00/67794 (43) International Publication Date: 16 November 2000 (16.11.00)
(21) International Application Number: PCT/US00/12405 (22) International Filing Date: 5 May 2000 (05.05.00) (30) Priority Data: 09/306,143 6 May 1999 (06.05.99) US 09/474,478 29 December 1999 (29.12.99) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 09/306,143 (CIP) Filed on 6 May 1999 (06.05.99) US 09/474,478 (CIP) Filed on 29 December 1999 (29.12.99) (71) Applicant (for all designated States except US): THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US]; West 116th Street and Broadway, New York, NY 10027 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): LONGLEY, B., Jack [US/US]; 49 Woodstock Road, Hamden, CT 06517 (US).	(74) Agent: WHITE, John, P.; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: METHODS FOR INHIBITING CUTANEOUS INFLAMMATION AND HYPERPIGMENTATION (57) Abstract This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a method of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHODS FOR INHIBITING CUTANEOUS
INFLAMMATION AND HYPERPIGMENTATION

This application claims priority of and is a continuation-in-
5 part of U.S. Serial No. 09/474,478, filed December 29, 1999,
which is a continuation-in-part of U.S. Serial No.
09/306,143, filed May 6, 1999, the contents of which are
hereby incorporated by reference into this application.

10 The invention described herein was made with Government
support under grant numbers 1 R29 AR 40514-01A1, 5 P30 041942
and 1-RO1-AR43356-01A2 from the National Institutes of
Health. Accordingly, the United States Government has
certain rights in this invention.

15 Throughout this application, various publications are
referenced by arabic numerals within parentheses. Disclosures
of these publications in their entirety are hereby
incorporated by reference into this application to more fully
20 describe the state of the art to which this invention
pertains. Full bibliographic citations for these references
may be found immediately preceding the claims.

Background of the Invention

25 The use of murine models to investigate human cutaneous
oncology, immunology and keratinocyte biology is advantageous
over the use of human skin for obvious reasons. However,
substantial differences exist between human skin and murine
skin. In human skin, Stem Cell Factor is produced by
30 epidermal keratinocytes after birth, unlike in normal murine
skin. The result of this, among other things, is that
melanocytes are present in the interadnexal epidermis in
human skin. In contrast, melanocytes in adult murine skin
are generally confined to hair follicles, with the exception
35 of rare epidermal melanocytes found in the ears, footpads,
and tail (1). A few dermal melanocytes may also be found in
mice, mostly in the ears. These differences have compromised
the use of the mice as a model system for investigation of

- 2 -

human cutaneous biology.

It has been discovered that melanocyte migration and development, as well as the survival of melanocytes and mast
5 cells, are dependent on expression of the kit protein, a receptor tyrosine kinase encoded by the c-kit proto-oncogene (2-6). The ligand for kit, known as stem cell factor (SCF) (also called mast cell growth factor, steel factor, and kit
10 ligand) may be produced locally in human skin by epidermal keratinocytes, fibroblasts, and endothelial cells (7-8). However, definitive studies of SCF production in murine skin have not been reported. Transgenic studies using the SCF gene promoter region and beta-galactosidase as a reporter gene suggest that, unlike in human skin, postnatal murine
15 cutaneous SCF expression is limited to the dermis and hair follicles, and not found in epidermal keratinocytes (9). The difference in SCF expression between human and murine epidermis could explain the difference in melanocyte distribution and other biological phenomena in these two
20 species.

SCF may be produced in two isoforms by alternate splicing of exon 6. One isoform lacks exon 6 encoded sequences and exists predominantly as a membrane-bound molecule. The other
25 isoform contains exon 6 encoded sequences which include a protease sensitive site (10-19). Cleavage at the protease sensitive site causes the release of a soluble, bioactive form of SCF. The membrane-bound and soluble forms of SCF have differential effects on melanocyte precursor dispersal
30 and survival (20) and exogenous soluble SCF may produce cutaneous mast cell hyperplasia and cutaneous hyperpigmentation (21-23). In addition, local high concentrations of soluble SCF have been found in lesions of human cutaneous mastocytosis, a disease characterized by
35 dermal accumulations of mast cells and increased epidermal melanin (7, 8, 24) and in spongiotic dermatitis, a common inflammatory condition of human skin (our unpublished data).

Summary of the Invention

This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject.

This invention provides a method of preventing or treating in a subject hyperpigmentation which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat hyperpigmentation so as to thereby prevent or treat hyperpigmentation in the subject.

This invention provides a method of preventing or treating in a subject asthma which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat asthma so as to thereby prevent or treat asthma in the subject.

This invention provides a method of preventing or treating in a subject cutaneous inflammation which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat cutaneous inflammation so as to thereby prevent or treat cutaneous inflammation in the subject.

This invention provides a method of preventing or treating in a subject anaphylaxis and bronchospasm which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat anaphylaxis and bronchospasm so as to thereby prevent or treat anaphylaxis and bronchospasm in the subject.

- 4 -

This invention provides a method of preventing or treating in a subject mastocytosis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or
5 treat mastocytosis so as to thereby prevent or treat mastocytosis in the subject.

This invention provides a method of preventing or treating in a subject urticaria which comprises administering to the
10 subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat urticaria so as to thereby prevent or treat urticaria in the subject.

15 This invention provides a method of preventing or treating in a subject hypersensitivity reactions which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat hypersensitivity reactions so
20 as to thereby prevent or treat hypersensitivity reactions in the subject.

This invention provides a method of preventing or treating in a subject airway inflammation which comprises
25 administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat airway inflammation so as to thereby prevent or treat airway inflammation in the subject.

30 This invention provides a method of preventing or treating in a subject interstitial cystitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat interstitial cystitis so as to
35 thereby prevent or treat interstitial cystitis in the subject.

This invention provides a method of preventing or treating

- 5 -

in a subject a tumor which expresses activated kit which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat a tumor which expresses
5 activated kit so as to thereby prevent or treat a tumor which expresses activated kit in the subject.

The invention provides a method of providing contraception to a subject which comprises administering to the subject an
10 amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent conception so as to thereby provide contraception to the subject.

This invention provides a method of desensitizing a subject
15 to an agent which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to desensitize the subject to the agent so as to thereby desensitize the subject to the agent.

20

- 6 -

Brief Description of the Figures

Figure 1:

Transgene design. Both transgenes used the human keratin 14 promoter and polyadenylation sequences. Transgene one included a rabbit b-globin intron, and transgene two included human growth hormone sequences to provide for stability. Neither the beta globin intron nor the human growth hormone sequences produce protein products.

10

Figure 2:

Increased mast cells in mice expressing epidermal membrane and soluble SCF (transgene one). (a) Numerous mast cells are demonstrated in the superficial dermis of body wall skin of newborn mice bearing transgene one (membrane/soluble SCF), using an immunoperoxidase/alcian blue technique which stain mast cell granules metachromatically purple. Note the apposition of mast cells (arrowheads) to basilar keratinocytes, the source of SCF. Immunoperoxidase with an anti-S100 antibody in this preparation also demonstrates melanocytes as brown staining cells in the epidermal basilar layers of epidermis and follicles (white arrows). Sebocytes are seen as large, round, lightly S-100(+) cells in the follicular epithelium. Melanin pigment is stained black in this preparation. (b) Immunofluorescence with anti-kit antibodies highlights kit expressing dermal mast cells (arrowheads) in body wall skin of newborn (transgene one membrane/soluble SCF) mouse. (c) Anti-kit antibody immunofluorescence shows mast cells crowded in the papillary dermis and extending into the upper reticular dermis and body wall skin of 21 day old, transgene one positive mouse, MC, confluent mast cells; arrowheads, individual and small clusters of mast cells; E, epidermis; F, follicles; K, keratin layer. (d) Hematoxylin and eosin-stained sections show mast cells filling the superficial corium in section of tongue from a 21 day old, transgene one positive mouse. The lack of abundant melanocytes and melanophages in this anatomic site allows easy visualization of the mast cells.

- 7 -

This histologic picture is identical to that seen in human cutaneous mastocytosis. (e) Alcian blue stained serial section of tongue shows metachromatic granules in mast cells of 21 day old, transgene one positive mouse.

5

Figure 3:

Electron microscopy confirms the presence of melanocytes and mast cells in transgenic mice. (a) Transgene one mouse with membrane/soluble epidermal SCF has numerous dermal mast cells (arrowheads) as well as dermal melanocytes (arrows). Asterisks show the boundary of the dermis and hair follicle. Higher magnification images of mast cell and melanocyte are shown in b and c, respectively. Original magnifications: (a) 2,750, (b) 9,000, (c) 11,750.

15

Figure 4:

Transgenic phenotypes are stable across a wide range of gene expression levels. This figure compares the transgene copy number determined by PCR, with SCF mRNA expression as determined by RNase protection assay, in lines from different founders. The relative density of SCF bands was determined by dividing the mean density of the SCF band by the density of a SCF band derived from an identical aliquot of RNA. Probe templates were 384 bases in length for SCF (40 base pairs of promoter sequence and 342 bases complementary to nucleotides 814-1156 of murine SCF mRNA (5)). A beta-actin probe was used as a control, and to allow standardization between RNA preparations from different mice. The beta-actin probe length was 310 bases, 227 bases of which are complementary to murine beta-actin mRNA. The probe was purchased from Ambion (pTR1-beta-actin-mouse anti-sense control template). Note the differences between TG2 (4x, 5x, 10x) and TG1 (6x).

20
25
30

Figure 5:

Epidermal SCF causes hyperpigmentation of murine skin. (a) Newborn mouse expressing membrane/ soluble SCF (transgene one, left) shows obvious hyperpigmentation compared to non-transgenic littermate (right). (b) Transgene two positive

35

mouse overexpressing membrane-bound epidermal SCF shows a similar phenotype with generalized hyperpigmentation which is most discernible in the ventral and hairless areas, and which is maintained in adult life. Three week old transgenic
5 (left) and non-transgenic littermate (right)

Figure 6:

Intraepidermal melanocytes are increased in transgenic mice.
(a) Tail skin section from 21 day old mouse expressing
10 epidermal membrane-bound SCF (transgene two) shows mild epidermal hyperplasia and a markedly increased number of melanocytes, identified as cells surrounded by clear halos, mostly at the dermal-epidermal junction. These mice also show extensive black epidermal melanin pigment (400x). (b)
15 Note the lack of both basilar melanocytes and epidermal pigment in the skin of the transgene (-) littermate control mouse (C57 black 6 (400x)). (c) Epidermal melanocytes express kit protein. Immunofluorescence staining with anti-kit antibody and Texas Red labeled secondary antibody
20 demonstrates confluent dendritic cells in the epidermal basalar layer of mice expressing membrane-bound SCF (transgene two arrows). These cells correspond to the S-100 protein (+) basilar dendritic cells seen in Figure 2a. Note two strongly kit positive solitary mast cells in the dermis
25 (arrowheads, 400x). Light staining of dendritic melanocytes can also be seen in the epidermis of transgene one positive mice (please see figure 2b).

Figure 7:

30 Electron microscopy confirms the presence of epidermal melanocytes in both types of transgenic mice. (a) Electron microscopy shows numerous keratinocytes containing phagocytized melanin granules in the interadnexal epidermis of mice expressing membrane-bound epidermal SCF (3500x). b.
35 Epidermal melanosomes, some marked with large arrows, are present in both keratinocytes and melanocytes. Pre melanosomes, marked with the open arrows, demonstrate the presence of a melanocyte. Note keratinocyte hemidesmosomes

- 9 -

(small arrows) which confirm the location of the melanocyte within the epidermis (16, 320x).

Figure 8:

5 Allergic ear swelling is significantly increased in SCF transgenic animals, and is reduced by blocking the SCF receptor with the ACK2 monoclonal antibody. All transgenic mice show increased ear swelling in response to allergic contactants compared to non-transgenic animals ($p \leq$
10 0.0001), showing that SCF contributes to dermatitis. Similar results are seen with irritant contactants (data not shown). The ear swelling is specifically decreased by the ACK2 monoclonal antibody which blocks the SCF receptor ($p \leq 0.05$) confirming that epidermal SCF plays an active role in
15 cutaneous inflammation.

Figure 9:

(a) An unpublished immunoperoxidase study of inflamed human skin with an anti-human SCF monoclonal anti-body shows
20 soluble epidermal SCF in spongiotic (eczematous) dermatitis, here demonstrated in an epidermal spongiotic vesicle. Human spongiotic dermatitis may be associated with hyperpigmentation. Soluble epidermal SCF is not detected in normal skin with this technique (7), suggesting that
25 epidermal SCF is released in cutaneous inflammatory states.
(b) Irritant dermatitis induced in transgenic mice by Croton oil is characterized histologically by spongiotic (eczematous) dermatitis. The murine dermatitis is shown in a hematoxylin and eosin stained slide because no satisfactory
30 antibody against murine SCF is available to allow demonstration of soluble SCF by immunoperoxidases. However, these results combined with the ACK2 blocking studies shown above implicate epidermal SCF in this phenomenon.

35 Figure 10:

Ear swelling response to croton oil in the 4202 (1x) strain of epidermal SCF transgenic mice. Significance levels by Mann-Whitney U Test.

- 10 -

Figure 11:

Ear swelling response of the 4197 (1x) strain of transgenic mice. Significance levels use Mann-Whitney U test. Results are even more significant if analyzed by ANOVA with a mixed effects model ($p < 0.001$).

Figure 12:

Irritant dermatitis caused by croton oil is decreased by blocking KIT signaling with anti-KIT monoclonal antibody, as evidenced by decreased ear swelling in 4197 (1x) SCF transgenic mice. $P < 0.02$ by ANOVA with mixed effects models. Please note that the ear swelling of 0.02mm at 48 hours in the KIT inhibited group is statistically identical to that of the non-transgenic mice (not treated with antibody, see Figure 10).

Figure 13:

Effect of ACK2 on the 24-hour passive cutaneous anaphylaxis (PCA) in mice. Each amount of dye represents the mean \pm S.E. of 4 experiments. Treatment with saline measured O.D. of extracted dye at 0.0075 ± 0.0015 . Treatment with Anti-DNP IgE measured O.D. of extracted dye at $0.0587 \pm 0.0096'$. Treatment with Control IgG + Anti-DNP IgE measured O.D. of extracted dye at $0.0571 \pm 0.0064'$. Treatment with ACK2 + Anti-DNP IgE measured O.D. of extracted dye at $0.0223 \pm 0.0049''$.

' $p < 0.01$ vs. Saline group.

'' $p < 0.01$ vs. anti-DNP IgE group.

- 11 -

Detailed Description of the Invention

This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject.

10 This invention provides a method of preventing or treating in a subject hyperpigmentation which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat hyperpigmentation so as to thereby prevent or treat hyperpigmentation in the subject.

This invention also provides a method of preventing or treating spongiotic dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat spongiotic dermatitis so as to thereby prevent or treat spongiotic dermatitis in the subject. As used herein, "spongiotic dermatitis" includes but is not limited to contact dermatitis.

25 This invention provides a method of preventing or treating in a subject asthma which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat asthma so as to thereby prevent or treat asthma in the subject.

This invention provides a method of preventing or treating in a subject cutaneous inflammation which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat cutaneous inflammation so as to thereby prevent or treat cutaneous inflammation in the

- 12 -

subject.

This invention provides a method of preventing or treating in a subject anaphylaxis and bronchospasm which comprises
5 administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat anaphylaxis and bronchospasm so as to thereby prevent or treat anaphylaxis and bronchospasm in the subject.

10 This invention provides a method of preventing or treating in a subject mastocytosis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or
15 treat mastocytosis so as to thereby prevent or treat mastocytosis in the subject.

This invention provides a method of preventing or treating in a subject urticaria which comprises administering to the
20 subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat urticaria so as to thereby prevent or treat urticaria in the subject.

25 This invention provides a method of preventing or treating in a subject hypersensitivity reactions which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat hypersensitivity reactions so
30 as to thereby prevent or treat hypersensitivity reactions in the subject.

This invention provides a method of preventing or treating in a subject airway inflammation which comprises
35 administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat airway inflammation so as to thereby prevent or treat airway inflammation in the subject.

- 13 -

In one embodiment, the airway inflammation is rhinitis. In another embodiment, the airway inflammation is sinusitis.

This invention provides a method of preventing or treating
5 in a subject interstitial cystitis which comprises
administering to the subject an amount of a compound capable
of inhibiting the stem cell factor signaling pathway
effective to prevent or treat interstitial cystitis so as to
thereby prevent or treat interstitial cystitis in the
10 subject. As used herein, "interstitial cystitis" includes
bladder inflammation.

This invention provides a method of preventing or treating
in a subject a tumor which expresses activated kit which
15 comprises administering to the subject an amount of a
compound capable of inhibiting the stem cell factor signaling
pathway effective to prevent or treat a tumor which expresses
activated kit so as to thereby prevent or treat a tumor which
expresses activated kit in the subject.

20

In one embodiment, the tumor is a mast cell tumor. In another
embodiment, the tumor is a gastrointestinal stromal tumor.
In another embodiment, the tumor is a germ cell tumor.

25 In one embodiment, the above method comprises inhibiting the
kinase enzymatic reaction of kit protein.

In one embodiment, the above method comprises inhibiting
chymase, elastase or other SCF cleaving enzymes.

30

In one embodiment, the above method comprises inhibiting
ligand binding with an antibody, peptide, or nonpeptide
chemical.

35 In one embodiment, the above method comprises inhibiting
receptor dimerization with an antibody, peptide, or
nonpeptide chemical.

- 14 -

In one embodiment of the above method, downstream signaling of the kit activation pathway is inhibited by blocking substrate association with the kit kinase domain.

- 5 In one embodiment of the above method, downstream signaling of the kit activation pathway is inhibited by blocking enzymatic function in the downstream signaling pathway.

- 10 In one embodiment of the above method, downstream signaling of the kit activation pathway is inhibited by blocking binding of molecules in the downstream signaling pathway.

- In one embodiment of the above method, the compound is an antibody or portion thereof. In one embodiment, the antibody
15 is a monoclonal antibody. In one embodiment, the monoclonal antibody is a human, humanized or a chimeric antibody. In one embodiment, the monoclonal antibody is an anti-kit antibody. In one embodiment, the anti-kit antibody is ACK2.

- 20 This invention provides the above method, wherein the compound comprises a Fab fragment of an anti-kit antibody.

- This invention provides the above method, wherein the compound comprises the variable domain of an anti-kit
25 antibody.

- This invention provides the above method, wherein the compound comprises one or more CDR portions of an anti-kit
30 antibody.

- This invention provides the above method, wherein the antibody is selected from the group consisting of IgA, IgD, IgE, IgG and IgM.

- 35 This invention provides the above method, wherein the compound comprises a peptide, peptidomimetic, a nucleic acid, or an organic compound with a molecular weight less than 500 Daltons.

- 15 -

This invention provides the above method, wherein the compound is sSCF, sKIT ligand or a fragment thereof. As used herein "sSCF" can also mean "sKIT ligand."

5 This invention provides the above method, wherein the compound is sKIT or a fragment thereof.

This invention provides the above method, wherein the subject is a mammal. The subject of the above methods includes but
10 is not limited to a mammal. The subject may be a mammal or non-mammal. The subject may be a human, a primate, an equine subject, an opine subject, an avian subject, a bovine subject, a porcine, a canine, a feline or a murine subject. In another embodiment, the subject is a vertebrate. In a
15 preferred embodiment, the mammal is a human being.

This invention provides the above method, wherein the administration is intralesional, intraperitoneal, intramuscular, subcutaneous, intravenous, liposome mediated
20 delivery, transmucosal, intestinal, topical, nasal, oral, anal, ocular or otic, intravesicular, or parenteral delivery.

This invention provides a method of providing contraception to a subject which comprises administering to the subject an
25 amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent conception so as to thereby provide contraception to the subject. In one embodiment, the subject is a male subject. In another embodiment, the subject is a female subject.

30 This invention provides the above method which comprises inhibiting the kinase enzymatic reaction of kit protein.

This invention provides the above method comprises inhibiting
35 chymase, elastase or other SCF cleaving enzymes.

This invention provides a method of desensitizing a subject to an agent which comprises administering to the subject an

- 16 -

amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to desensitize the subject to the agent so as to thereby desensitize the subject to the agent.

5

For example, the agent can be one which causes an allergic or other immune response in a subject. Examples of agents include but are not limited to workplace chemicals or pollens.

10

One skilled in the art can employ various methods for determining whether a compound inhibits the stem cell signaling pathway. One of these methods comprises:

- a) immobilizing kit protein on a solid matrix;
- 15 b) contacting the immobilized kit protein with the compound being tested and a predetermined amount of SCF under conditions permitting binding of kit protein and SCF in the absence of the compound;
- c) removing any unbound compound and any unbound SCF;
- 20 d) measuring the amount of SCF which is bound to the immobilized kit protein;
- e) comparing the amount measured in step (d) with the amount measured in the absence of the compound, a decrease in the amount of SCF bound to the kit
- 25 protein in the presence of the compound indicating that the compound inhibits binding of SCF to kit protein, thereby indicating that the compound inhibits the stem cell factor signaling pathway.

30 Another method includes detecting in vitro phosphorylation of kit comprising the following steps:

1. Cells expressing KIT, either naturally occurring as in the C2, BR, P815, or HMC1 lines, or as the
- 35 result of DNA transfection, are grown in vitro in the absence of exogenous SCF.
2. The cells are treated with the compound or substance. In the case of cells expressing wild

- 17 -

type (non-mutated and not constitutively activated) KIT, treatment with the substance or compound may be followed by treatment with SCF. Controls include cells treated with compound or substance, and not exposed to SCF.

5

3. The cells are lysed and KIT is immunoprecipitated, electrophoresed, blotted with anti-phosphotyrosine antibody, and the antibody detected by chemiluminescence or radioactive labeling and autoradiography, thereby determining the level of KIT phosphorylation on tyrosine.

10

4. The level of KIT phosphorylation on tyrosine in cells not exposed to the compound or substance is compared to KIT phosphorylation on tyrosine in cells exposed to the compound or substance. A decrease in KIT phosphorylation on tyrosine in the treated cells indicates that the compound or substance inhibits the SCF signaling pathway.

15

20

A cell proliferation and viability method comprises the following steps:

1. Cells expressing KIT, and depending on KIT activation for survival, are grown in the presence of SCF if they express wild type KIT or in the absence of SCF if they express mutated and constitutively activated KIT.

25

2. The cells are grown in replicate tissue culture wells, in the presence or absence of the compound or substance to be tested, and the number of viable and non-viable cells per well is determined daily by counting a sample of cells in a hemocytometer. The number of viable and non-viable cells are determined by the trypan blue exclusion method.

30

35

3. A decrease in cell growth, as determined by the presence of fewer viable cells in the wells treated with the compound or substance compared to

- 18 -

the cells in the wells not so treated, indicates that the compound or substance interferes with the KIT SCF signaling pathway.

- 5 4. Alternatively, cell growth may be determined by measuring cellular incorporation of labeled substances such as tritium labeled thymidine.

The present invention provides a method of identifying a composition, a compound or a procedure which can produce a
10 skin response in a subject, comprising: a) administering said composition or compound, or applying said procedure to the transgenic mice which express endogenous epidermal stem cell factor, and b) analyzing the contacted skin for response.

- 15 In one embodiment of the method, the composition or compound can be administered orally or by injection.

In another embodiment of the method, the composition or compound can be administered topically by contacting the
20 composition or compound with the skin of the transgenic mice.

In another embodiment of the method, the procedure is not previously known.

- 25 In another embodiment of the method, the procedure is identified by the method.

In another embodiment of the method, the procedure is DNA vaccination.

30

In this invention, the skin response may be induced. This skin response includes but is not limited to inflammation, tanning, melanoma, carcinoma or hyperpigmentation.

- 35 In another embodiment of the method, the composition may be cosmetics, medications or skin care products.

In another embodiment of the method, the composition or

- 19 -

compound is not previously known.

In yet another embodiment of the method, the composition or compound is identified by the method.

5

In a further embodiment of the method, a mixture is produced for producing a skin response comprising an effective amount of the composition or compound identified by the method and a suitable carrier.

10

The present invention also provides a method of identifying a composition, a compound, or a procedure which can reduce or treat skin response in a subject, comprising: a) administering said composition or compound, or applying said
15 procedure to the transgenic mice which express endogenous epidermal stem cell factor and which had been induced to produce a skin response and b) analyzing the skin of said transgenic mice to determine the reduction of skin response, wherein the reduction of skin response indicates that the
20 composition, compound, or procedure can reduce skin response.

In one embodiment of the method, the composition or compound can be administered orally or by injection.

25 In another embodiment of the method, the composition or compound can be administered topically by contacting the composition or compound with the skin of the transgenic mice.

In another embodiment of the method, the procedure is not
30 previously known.

In another embodiment of the method, the procedure is identified by the method.

35 In another embodiment of the method, the procedure is DNA vaccination.

In another embodiment of the method, the composition or

- 20 -

compound is not previously known.

In another embodiment of the method, the composition or compound is identified by the method.

5

In another embodiment of the method, a mixture is produced for reducing skin response comprising an effective amount of the composition or compound identified by the method and a suitable carrier.

10

In another embodiment of the method, the skin response is inflammation, tanning, skin carcinoma, melanoma or hyperpigmentation.

15 In another embodiment of the method, the hyperpigmentation is natural occurring hyperpigmentation or post inflammatory hyperpigmentation.

In another embodiment of the method, the inflammation is associated with human hyperpigmentation, or human hypopigmentation.

20

In another embodiment of the method, the subject is a mouse or a human-being.

25

In another embodiment of the method, the epidermal stem cell factor transgene encodes either a membrane bound epidermal stem cell factor or a membrane/soluble epidermal stem cell factor.

30

In another embodiment of the method, the epidermal stem cell factor transgene encodes a membrane or soluble epidermal stem cell factor.

35 In another embodiment of the method, the epidermal stem cell factor transgene is cloned into a construct containing a human cytokeratin 14 promotor.

- 21 -

In another embodiment of the method, the human cytokерatin 14 promotor causes the expression of the stem cell factor transgene in murine skin of the basal layers of the interadnexal epidermis and the follicular epithelium.

5

In another embodiment of the method, the skin response of the transgenic mice can be induced by applying an irritant or an allergic dermatitis inducing agent to said skin.

10 In another embodiment of the method, the irritant is croton oil or dinitrofluorobenzene.

In another embodiment of the method, the croton oil or dinitrofluorobenzene are applied to the ear or the abdominal skin of the transgenic mice; wherein the abdominal skin is either hairless or shaved.

15

In another embodiment of the method, the croton oil is used at a concentration of 0.2 percent.

20

In another embodiment of the method, the dinitrofluorobenzene is used at a concentration of 0.5 percent in a 4:1 mixture of acetone and olive oil.

25 In another embodiment of the method, the reduction or treatment of hyperpigmentation is determined by electron microscopic analysis.

In another embodiment of the method, the compound is an epidermal stem cell factor inhibitor.

30

In yet another embodiment of the method, the stem cell factor inhibitor is a monoclonal antibody.

35 In a further embodiment of the method, the monoclonal antibody is ACK2.

The present invention further provides a method of

- 22 -

identifying a composition, a compound or a procedure which can reduce radiation damage to the skin of a subject, comprising: a) administering said composition or compound, or applying said procedure to the transgenic mice which
5 express endogenous epidermal stem cell factor, b) subjecting the skin of said transgenic mice and the skin of the control transgenic mice to radiation, and c) analyzing the effects of said composition, compound, or procedure on reducing skin radiation damages.

10

In one embodiment of the method, the composition or compound can be administered orally or by injection.

In another embodiment of the method, the composition or
15 compound can be administered topically by contacting the composition or compound with the skin of the transgenic mice.

In another embodiment of the method, the procedure is not previously known.

20

In another embodiment of the method, the procedure is identified by the method.

In another embodiment of the method, the procedure is DNA
25 vaccination.

In another embodiment of the method, the composition or compound is not previously known.

30 In another embodiment of the method, the composition or compound is identified by the method.

In another embodiment of the method, a mixture is produced for reducing skin radiation damages comprising an effective
35 amount of the composition or compound identified by the method and a suitable carrier.

In yet another embodiment of the method, the radiation is

- 23 -

ultra-violet light.

In a further embodiment of the method, the radiation damage is tanning, carcinogenesis, photo-aging, photo-damage or the development of melanoma.

The present invention also provides a pharmaceutical composition for treating human skin diseases, comprising (a) a compound that can treat skin diseases of the transgenic mice which express endogenous epidermal stem cell factor, and (b) a suitable carrier, wherein the compound specifically targets the epidermal stem cell factor or its receptor.

In one embodiment of the pharmaceutical composition, the compound is ACK2.

This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.

25

Experimental Details

Transgene construction:

Two murine SCF cDNAs were cloned into constructs containing the human cytokeratin 14 upstream region (27) (Figure 1). This promoter causes expression in the skin limited to the basal layers of the interadnexal epidermis and the follicular epithelium. The cDNAs were both full length clones, containing exon 6 encoded sequences. One cDNA (transgene one) was unmodified and therefore could produce a membrane-bound protein with the exon 6 encoded protease sensitive site, from which a soluble, bioactive form of SCF could be efficiently generated (10, 11, 28). The product of

- 24 -

this transgene will be referred to as membrane/soluble SCF. The second cDNA (transgene two) had been previously modified by site directed mutagenesis, deleting the primary high efficiency cleavage site (between amino acids 164 and 165) and an alternate exon 7 encoded low efficiency cleavage site (found in murine SCF between amino acids 180 and 181). The SCF produced by this transgene therefore exists predominantly as a membrane-bound molecule (membrane SCF) (29). Both cDNAs have been previously shown to produce biologically active SCF (29, 30).

Generation and analysis of transgenic animals:

Two $\mu\text{g/ml}$ transgenic DNA, in 10 mM Tris (pH 7.5), 0.1 mM EDTA was injected into fertilized oocytes collected from pseudopregnant mice as described (31). At birth, most transgene expressing mice could be identified by distinctive pigmentary phenotypes, as described in the Results section. Integration of transgenes was verified by polymerase chain reaction (PCR) of genomic DNA with transgene-specific primers and copy number estimated by Southern blotting of PCR products, followed by autoradiography and densitometry. Skin specific expression of transgene messenger RNA was confirmed by northern blotting and by reverse transcription-polymerase chain reaction with transgene specific primers using RNA extracted from representative animals. Transgene expression was quantitated by RPA II Ribonuclease Protection Assay Kit (Ambion, Austin, TX, USA) according to the manufacturer's directions. Briefly, total RNA extracted from mouse skin was hybridized with digoxigenin labeled single stranded RNA probes for twenty three hours at 42°C , digested with RNase A and RNase T1, electrophoresed through 5% polyacrylamide/7 Molar urea, protected fragments were transferred to Hy⁺ membrane (Boehreringer-Mannheim, Indianapolis, IN, USA), bands detected by chemiluminescences, and band density determined by densitometry. Preliminary studies of RNA preparations from each transgenic line were performed to measure Beta-actin, and the amounts of RNA for SCF mRNA determinations adjusted for comparison. RNA was also used

- 25 -

with reverse transcription and the polymerase chain reaction for direct amplicon sequencing of c-kit mRNA sequences in regions which could contain known activating mutations, as previously described (25). The primers used were 5' CAAATC/GCATCCC/TCACACCCTGTTTAC and 5' CCATAAGCAGTTGCCTCAAC which bind to nucleotides 1568-1593 and 1854-1835 and 5' TGTATTACAGAGACTTGGC and 5' AAAATCCCATAGGACCAGAC binding to nucleotides 2384-2403 and 2595-2576. These regions contain the codons with both of the activating mutations, codon 559 and codon 814, respectively which have been described in human mastocytosis and in a murine mast cell line (5, 26).

Transgene one, containing the full-length unmodified SCF cDNA (membrane/soluble SCF), was injected into 100 F1 oocytes (C57 BL/6 x SLJ), which were implanted into six host mothers, resulting in four independent hyperpigmented mice, all of which were positive for the transgene, and 40 other littermates which were pigmented phenotype negative and transgene negative by PCR.

Oocytes for transgene two (membrane SCF) were F1 (C57BL/6J female x SLJ/J male), and the offspring could be black, agouti, or white. Injection of 40 embryos and implantation into six host mothers generated 48 pups, 21 of which were positive for integration by PCR. Of the 25 founder mice identified by PCR with the transgene specific primers, 3 were black, 13 were agouti, and 9 were white. Five PCR positive mice (3 agouti and 2 black) showed a clearly identifiable pigmented phenotype. Given the inability of white mice to produce normal cutaneous pigment, it is possible that there were also white founders that expressed the transgene without the production of an obvious change in pigment. Backcrossing of phenotype positive, black and agouti founders to C57 BL/6 mice produced uniform pigmented changes, described in the Results section.

Histology, immunohistochemistry, and electron microscopy:
Tissues from transgenic and littermate mice were fixed in

- 26 -

formalin and embedded in paraffin or polyester wax, sectioned, and stained with hematoxylin and eosin, azure blue, alcian blue, or Giemsa's stain according to standard techniques (31-33). Immunofluorescence studies were performed on polyester wax embedded sections or frozen sections, also using standard techniques. Antibodies included anti-S100 (rabbit anti-cow S100, pre-diluted, Dako, Carpinteria, CA), and the ACK2 and ACK4 monoclonals (rat anti-mouse c-kit (34), at 20 μ g/ml). Controls included omission of the primary antibody or the use of isotype matched monoclonal antibodies of irrelevant specificity. Electron microscopy was done as previously described (35).

Inflammation Inducement and Treatment

We used Croton Oil and dinitrofluorobenzene (DNFB), respectively to reduce irritant and allergic contact dermatitis, respectively, in HK14-SCF transgenic mice and their non-transgenic litter-mates. Croton Oil was applied directly to the ears of mice and DNFB was applied to the ears of mice after sensitization on shaved abdominal skin. Ear swelling was measured with a micrometer. In the ear-swelling test, the transgenic mice were divided into two groups; one group was treated with the murine monoclonal antibody ACK2, which blocks the interaction of SCF with its receptor (KIT), and the other group was treated with only saline. In addition, shaved abdominal skin of some mice was also treated with Croton Oil or with DNFB, and observed for inflammation and hyperpigmentation.

For statistical analysis, we used a mixed effects model, which allows us to fit repeated measurements over time and to compare different groups over time. We also performed orthogonal contrasts to evaluate the difference between treated and control groups at each time point. Immunoperoxidase study, using anti human SCF monoclonal antibodies, were performed in skin by standard method (7).

Experimental Results

- 27 -

Dermal mast cells accumulate in the presence of membrane/soluble keratinocyte SCF. Sections of skin from all mice producing membrane/soluble SCF (transgene one) showed increased mast cells in the dermis (Figure 2). In newborn
5 transgene one positive mice, the mast cells were superficial near the dermal-epidermal junction, close to the epidermal source of soluble SCF (Figure 2a). In older mice the mast cells filled the papillary dermis in some areas, but were also present in the reticular dermis, in a pattern identical
10 to that of human mastocytosis (Figure 2, b-d). Electron microscopic analysis confirmed the presence of numerous mast cells with characteristic granules within the dermis of the transgene one positive animals, and also showed that some of the heavily pigmented cells within the dermis of transgene
15 one positive mice were melanocytes (Figure 3). Mast cells were relatively rare and dermal melanocytes were not detected in the body wall skin of non-transgenic littermates and in transgene two positive animals of equivalent age. These observations were true across a wide range of copy numbers
20 and levels of SCF mRNA expression (Figure 4). Since the keratin 14 promoter is properly expressed in the skin only by keratinocytes, and since the production of only membrane-bound keratinocyte SCF did not spontaneously result in increased dermal mast cells in transgene two positive
25 animals, keratinocyte production of the soluble form of SCF appears to be able to cause cutaneous mastocytosis in mice.

SCF transgenic mice are hyperpigmented:

Targeted expression of each of the SCF transgenes in murine
30 skin caused a similar, distinctive pigmented phenotype. The pigment responsible for the coat color of normal mice resides in the hair follicles and hair shafts, not in the epidermis. The transgenic mice, however, developed prominent epidermal pigmentation (Figure 5). Transgene positive animals could
35 be identified by increased pigment at birth. By approximately 21 days of age, the phenotypes were well established; phenotype positive animals showed pigmentation of most of the skin as well as increased pigmentation of most

- 28 -

of their skin as well as coat pigment. Extensive pigmentation was noted in a number of areas including the nose, mouth, ears, paws, and external genitalia when compared to normal littermate controls. There was enough individual
5 variation in pigmentation so that no clear correlation between the level of pigmentation and the levels of transgenic expression could be shown. All transgenic animals showed similar degrees of pigmentation regardless of transgene type, copy number, or levels of SCF mRNA
10 expression. In addition to the epidermal pigmentation, the three transgene two positive agouti founders showed thin black transverse strips, consistent with the pigment distribution of the allophenic mice described by Beatrice Mintz (pictures not shown) (36).

15

Numerous melanocytes are maintained in the skin of transgenic mice:

The increased pigmentation of the skin of the transgene positive mice of both types is attributable to the presence
20 of intraepidermal melanocytes, and to the epidermal melanin produced by those cells. Intraepidermal melanocytes can be identified in hematoxylin and eosin stained sections as cells in the basilar layers surrounded by clear halos (Figure 6, a & b) or in immunoperoxidase preparations by their
25 expression of S-100 protein. Immunohistochemical analysis of animals expressing each of the transgenes showed numerous S-100(+) intraepidermal melanocytes (please also see Figure 2a). These melanocytes can be differentiated from Langerhans cells, which also express S-100 protein, because melanocytes
30 are in the basal layers and Langerhans are in the suprabasal layers. Melanocytes can also be differentiated from Langerhans cells by their expression of the kit protein, the receptor for SCF, which is not expressed by Langerhans cells. Staining of transgenic animal skin with anti-kit antibody
35 identified well-developed dendritic cells within the basilar layers of the epidermis and follicular epithelium, consistent with melanocytes (Figure 6c and 2b).

- 29 -

Histologic examination confirmed the presence of pigment within the epidermis of both transgene one and transgene two phenotype positive mice from all sites examined, including the ears, tail, footpads, and body wall (Figure 6a). In addition, transgene one positive mice showed many pigmented cells within the dermis. Pigmentary abnormalities were not observed in transgene negative littermates. Only slight epidermal pigment was identified in these control mice, and mostly in non-hair bearing areas like the footpad and tail. Although pigment patterns were stable throughout much of the adult life of the mice, an occasional TG1 (msSCF) mouse developed patchy areas of depigmentation, mostly in the ears, associated with loss of epidermal melanocytes and increased pigment incontinence. This phenomenon was not observed in the mSCF mice.

Electron microscopy confirmed the presence of numerous melanocytes within the epidermis of both types of transgenic mice (Figure 7). Pigmented keratinocytes, similar to those seen in the epidermis of humans, were also present in the interadnexal epidermis of the transgenic mice. Intraepidermal melanocytes and pigmented keratinocytes were extremely rare in control mice.

All transgenic mice showed ear swelling which was greater in magnitude and more prolonged than the non-transgenic (B6) control mice:

Blocking SCF by administration of ACK2 decreased the magnitude of ear swelling in transgenic mice, as shown in the following figure 8.

Averaging across time:

There is a difference between the ACK2 treated and the control saline treated transgenic mice, which is significant at the 0.05 level. Averaging across time, there is also a significant difference between each of the two groups of transgenic mice (ACK2 treated and control) and the non-transgenic mice. Both comparisons are statistically

- 30 -

significant at the 0.0001 level. See Figure 8. Observation of the abdominal wall skin treated with Croton Oil or DNFB showed hyperpigmentation and thickening which was not observed in non-transgenic mice control (B6) mice that were
5 treated identically. Histologically, hyperpigmentation correlated with dermal melanophages and increased epidermal melanin, identical to the changes seen in human postinflammatory hyperpigmentation.

10 Discussion

Melanocytes are maintained in human epidermis throughout life. In normal mice DOPA reaction positive cells (melanoblasts and melanocytes) are found in the epidermis at birth, but their number decreases from postnatal day 4 and
15 is severely reduced after one month of age (37). One possible explanation for the maintenance of epidermal melanocytes in human skin, and the difference between the distribution of melanocytes in adult human and murine skin, could be expression of epidermal SCF. Human epidermal
20 keratinocytes produce SCF (7, 8, 39), but the SCF gene does not appear to be expressed in murine epidermis (9). The results presented here show that SCF expression by murine epidermal keratinocytes causes the maintenance and stimulation of epidermal melanocytes throughout life. These
25 data support the hypothesis that the decrease in melanocyte numbers in the postnatal mouse epidermis is due to a lack of local SCF expression. In combination with the fact that the soluble SCF produced by Sl/Sld mice is insufficient to support normal melanocyte survival and the observations that
30 membrane-bound SCF promotes longer lasting kit activation and increased survival of kit dependent cells in the hematopoietic system (40,41), our data suggest that it is specifically the membrane-bound form of SCF that is crucial for melanocyte survival and function.

35

It is interesting to note that none of the animals expressing either of the transgenes described in this paper have developed melanoma to date, a finding which supports previous

- 31 -

observations that stimulation of the kit tyrosine kinase receptor does not appear to promote the development of melanocytic tumors (40). It also seems likely that the animals described herein, or animals derived from them, will
5 be useful in the study of cutaneous mastocytosis and epidermal melanocyte biology.

The fact that SCF transgenic mice have greater responses to allergic and irritant contactants shows that epidermal SCF
10 can actively contribute to eczematous dermatitis. This interpretation is confirmed by our demonstration that the inflammation can be diminished by blocking the SCF receptor with the ACK2 monoclonal antibody. Since human post natal epidermal keratinocytes express SCF, unlike post natal murine
15 epidermal keratinocytes, and alterations of human epidermal SCF are found in spongiotic dermatitis (a form of eczema), these observations also support our contention that the skin of mice expressing epidermal SCF is a better model of human skin than is the skin of normal mice. Further supporting
20 this claim is our previous observation of increased soluble epidermal SCF in the hyperpigmented lesions of mastocytosis. In sum, these data support our claim that animals expressing epidermal SCF are more suitable for a wide variety of investigations than those which do not.

25

Additional Experiments

A mouse model of human skin was used in which mice express transgenic SCF driven by the human keratin 1 promotor. Normal mice do not express epidermal SCF post-nataly, but humans and
30 the transgenic mice do. The epidermal SCF expressed by humans and by these mice can be solubilized in inflammatory reactions, and based on the data produced, the soluble SCF contributes to the inflammatory process. The trends seen have been repeatedly confirmed in multiple different transgenic
35 lines. The following data are representative of multiple experiments. A series of tests were conducted using croton oil as a skin irritant and 2,4 dinitro-fluro-benezne (DNFB) as a contact allergen to induce cutaneous delayed type

- 32 -

hypersensitivity (DTH). The results shown in figures 10-11 show that SCF-KIT signaling is directly involved in inflammatory responses and implicate epidermal SCF in both irritant contact dermatitis and cutaneous DTH.

5

These first experiments demonstrate that irritant dermatitis caused by croton oil is associated with increased ear swelling in epidermal SCF transgenics compared to normal mice (non-transgenic litter mates) (Figure 10). Similar results were seen with DTH to DNFB (Figure 11) To further test the hypothesis that SCF-KIT signaling contributes to this inflammation, a monoclonal antibody was used which binds to murine KIT and blocks its activation. As seen in Figures 12 and 8, this antibody inhibited the exaggerated ear swelling response seen in the transgenic animals.

15

It is important to note that the KIT blocking antibody can completely block the additional ear swelling attributable to SCF-KIT signaling in the response to croton oil. This is by definition the efferent (effector) arm of the immune response. The fact that the same antibody treatment does not completely abolish the allergic (DTH) response to DNFB shows, for the first time, that the afferent arm of the immune response is affected by SCF-KIT signaling. Since the antibody completely blocks the efferent effect, as evidenced by complete blocking of the response to croton oil, the portion of the increased transgenic response to DNFB that is not blocked must be attributable to the afferent arm of the immune response. This is a novel concept. Thus, interfering with SCF-KIT signaling during the afferent, sensitization phase of the immune response may be a powerful technique for preventing allergic and other untoward immune responses. For instance, blocking SCF-KIT signaling might be used to induce tolerance or to desensitize individuals to potential environmental sensitizing agents such as workplace chemicals or pollens.

25

30

35

Evidence for the relevance of these observations to human

- 33 -

skin may be summarized as follows: a) Normal murine post-natal keratinocytes do not produce SCF; b) it was previously discovered that human epidermal keratinocytes do produce SCF, and that it is normally present predominantly in a cell-associated, membrane-bound form; c) Human epidermal SCF is solubilized in the presence of neoplastic mast cells, presumably by chymase, implying that it may also be solubilized in inflammatory reactions; and d) soluble SCF staining patterns were observed that are similar to, but more subtle than, the solubilization occurring in lesions of cutaneous mastocytosis, in randomly selected cases of human spongiotic dermatitis.

It is believed that past failures to detect a critical role for SCF-KIT signaling in DTH rest on the fact that the mice that have been studied do not express epidermal SCF, and the contribution of SCF to murine cutaneous reactions, if there is any, has therefore been minimal. Since humans do express epidermal SCF, these novel and unexpected results are relevant to human health.

We conclude that inhibition of the SCF-KIT signaling pathway has a beneficial effect in treating human dermatitis of the irritant and DTH types.

25

30

35

REFERENCES

1. Silvers, W. K. (1979) "The coat colors of mice: a model for mammalian gene action and interaction" Springer-Verlag, Inc., New York. pp. 4-5 and references
5 therein;
2. Mayer, T. C. (1970) "A comparison of pigment cell development in albino, steel, and dominant-spotting mutant mouse embryos" Develop. Biol., 23:297-309;
10
3. Russell, E. S. (1979) "Hereditary anemias of the mouse: a review for geneticists" Adv. Genet. 20:357-459;
4. Yarden, Y., et al. (1987) "Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an
15 unidentified ligand" EMBO J., 6:3341-3351;
5. Qiu, F. H., et al. (1988) "Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family -- oncogenic activation of v-kit involves deletion of
20 extracellular domain and C terminus" EMBO J., 7:1003-1011;
6. Geissler, E. N., et al. (1988) "The dominant-white spotting (W) locus of the mouse encodes the c-kit
25 proto-oncogene" Cell, 55:185-192;
7. Longley, B. J. Jr, et al. (1993) "Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous
30 mastocytosis" N. Engl. J. Med., 328:1302-1307;
8. Weiss, R. R., et al. (1995) "Human dermal endothelial cells express membrane-associated mast cell growth factor" J. Invest. Dermatol., 104:101-106;
- 35 9. Yoshida, H., et al. (1996) "Neural and skin cell specific expression pattern conferred by Steel factor regulatory sequence in transgenic mice" Developmental Dynamics, 207:222-232;

- 35 -

10. Anderson, D. M., et al. (1990) "Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms" Cell, 63:235-243;
11. Zsebo, K. M., et al. (1990) "Identification, purification, and biological characterization of hematopoietic stem cell factor from Buffalo rat liver-conditioned medium" Cell, 63:195-201;
12. Flanagan, J. G. and P. Leder (1990) "The kit ligand: a cell surface molecule altered in steel mutant fibroblasts" Cell, 63:185-194;
13. Onoue, H., et al. (1989) "Suppressive effects of S1/Sld mouse embryo-derived fibroblast cell lines on diffusible factor-dependent proliferation of mast cells" Blood, 74:1557-1562;
14. Anderson, D. M., et al. (1991) "Alternate splicing of mRNAs encoding human mast cell growth factor and localization of the gene to chromosome 12q22-q24" Cell Growth & Development, 2:373-378;
15. Lu, H. S., et al. (1991) "Amino acid sequence and post-translational modification of stem cell factor isolated from buffalo rat liver cell-conditioned medium" J. Biol. Chem., 266:8102-8107;
16. Flanagan, J. G., et al. (1991) "Transmembrane form of the kit ligand growth factor is determined by alternative splicing and is missing Sld mutant" Cell, 64:1025-1035;
17. Brannan, C. I., et al. (1991) "Steel-Dickie mutation encodes a c-Kit ligand lacking transmembrane and cytoplasmic domains" Proc. Natl. Acad. Sci. USA,

- 36 -

88:4671-4674;

18. Zsebo, K. M., et al. (1990) "Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor" Cell, 63:213-224;
19. Huang, E. J., et al. (1992) "Differential expression and processing of two cell associated forms of the kit-ligand: KL-1 and KL-2" Mol. Biol. Cell, 3:349-362;
20. Wehrle-Haller, B. and J. A. Weston (1995) "Soluble and cell-bound forms of steel factor activity play distinct roles in melanocyte precursor dispersal and survival on the lateral neural crest migration pathway" Development, 121:731-742;
21. Tsai, M., et al. (1991) "The rat c-kit ligand, stem cell factor, induces the development of connective tissue-type and mucosal mast cells in vivo: Analysis by anatomical distribution, histochemistry, and protease phenotype" J. Exp. Med., 174:125-131;
22. Harrist, T. J., et al. (1995) "Recombinant human stem cell factor (SCF) (c-kit ligand) promotes melanocyte hyperplasia and activation in vivo" Lab. Invest., 72:48A;
23. Costa, J. J., et al. (1996) "Recombinant human stem cell factor (KIT ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo" J. Exp. Med., 183:2681-2686;
24. Longley, B. J., et al. (1995) "The mast cell and mast cell disease" J. Am. Acad. Dermatol., 32:545-561;
25. Longley, B. J., et al. (1996) "Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human

- 37 -

mast cell neoplasm" Nature Genetics, 12:312-314;

26. Furitsu, T., et al. (1993) "Identification of mutations
in the coding sequence of the proto-oncogene c-KIT in
5 a human mast cell leukemia cell line causing
ligand-independent activation of c-KIT product" J. Clin.
Invest., 92:1736-1744;
27. Vassar, R., et al. (1989) "Tissue-specific and
10 differentiation-specific expression of a human K14
keratin gene in transgenic mice" Proc. Natl. Acad. Sci.
USA, 86:1563-1567;
28. Williams, D. E., et al. (1990) "Identification of a
15 ligand for the c-kit proto-oncogene" Cell,
1990;63:167-174;
29. Majumdar, M. K., et al. (1994) "Identification and
mutation of primary and secondary proteolytic cleavage
20 sites in murine stem cell factor cDNA yields
biologically active, cell-associated protein" J. Biol.
Chem., 269:1237-1242;
30. Yasunaga, M., et al. (1995) "Cell cycle control of
25 c-kit-1⁺ IL-7R1B precursor cells by two distinct signals
derived from IL-7 receptor and c-kit in a fully defined
medium" J. Exp. Med., 182:315-323;
31. Kunisada, T., et al. (1996) "Characterization and
30 isolation of melanocyte progenitors from mouse embryos"
Development Growth & Differentiation, 38:87-97;
32. Yoshida, H., et al. (1996) "Distinct stages of
melanocyte differentiation revealed by analysis of
35 nonuniform pigmentation patterns" Development,
122:1207-1214;
33. Scott, J. E. and R. T. Mowry (1970) "Alcian blue - a

- 38 -

consumer's guide" J. Histochem. Cytochem., 18:842;

34. Nishikawa, S., et al. (1991) "In utero manipulation of coat color formation by a monoclonal anti-c-kit antibody: two distinct waves of c-kit-dependency during melanocyte development" EMBO J., 10:2111-2118;
35. Okura, M., et al. (1995) "Effects of monoclonal anti-c-kit antibody (ACK2) on melanocytes in newborn mice" J. Invest. Dermatol., 105:322-328;
36. Bradl, M., et al. (1991) "Clonal coat color variation due to a transforming gene expressed in melanocytes of transgenic mice" Proc. Natl. Acad. Sci. USA, 88:6447-6451;
37. Grichnik, J. M., et al. (1995) "Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients" J. Am. Acad. Dermatol., 33:577-583;
38. Hirobe, T. (1984) "Histochemical survey of the distribution of the epidermal melanoblasts and melanocytes in the mouse during fetal and postnatal periods" Anat. Rec., 208:589-594;
39. Hamann, K., et al. (1995) "Expression of stem cell factor in cutaneous mastocytosis" Br. J. Dermatol., 133:203-208;
40. Funasaka, Y., et al. (1992) "C-kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas" Mol. Biol. Cell, 3:197-209.

- 39 -

SECOND SERIES

Mastocytosis is a neoplastic disease caused at least in part by somatic mutations of the *c-KIT* proto-oncogene resulting in constitutive activation of its protein product, KIT, the
5 receptor tyrosine kinase for stem cell factor. KIT stimulates mast cell proliferation and prevents apoptosis of neoplastic mast cells. Human gastrointestinal stromal tumor cells also express mutated and activated kit (Hirota et al 1998). To develop potential therapies for mastocytosis and
10 gastrointestinal stromal tumor cells we used indolinones, small molecules which inhibit tyrosine kinases.

The proto-oncogene *c-KIT* encodes KIT (Yarden et al, 1987; Qiu et al, 1988), the receptor tyrosine kinase for stem cell
15 factor (Martin et al, 1990), also known as mast cell growth factor. Somatic *c-KIT* mutations causing ligand-independent activation of KIT and cell transformation (Furitsu et al, 1993; Kitayama et al, 1995; Tsujimura et al, 1996; Hirota et al, 1998; Ma et al, 1999a) appear causal in certain types of
20 mastocytosis (Nagata et al, 1995; Longley et al, 1996, 1999; Ma et al, 1999a).

Documented activating *c-KIT* mutations fall into two groups. One group consists of mutations in codon 816 of human *c-KIT*,
25 or its equivalent positions in other species, resulting in single residue substitution for Asp816 in the activation loop of the receptor kinase domain (Ma et al, 1999a). The other group of activating mutations includes single residue substitutions and in-frame insertions or deletions in the
30 receptor intracellular juxtamembrane region, which disrupt intramolecular inhibition of the kinase by a putative juxtamembrane α -helix (Ma et al, 1999b). All sporadic adult-onset mastocytosis patients examined to date, and a subset of pediatric cases with atypical clinical presentations, have
35 activating codon 816 mutations (Longley et al, 1999), whereas

- 40 -

activating juxtamembrane mutations are common in canine mastocytomas (Ma et al, 1999a) and in human gastrointestinal stromal tumors (Hirota et al, 1998).

5

References for second series

Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, et al:
Identification of mutations in the coding sequence of the
proto-oncogene *c-kit* in a human mast cell leukemia cell line
10 causing ligand-independent activation of *c-kit* product. *J*
Clin Invest 92: 1736-1744, 1993

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, et
al: Gain-of-function mutations of *c-kit* in human
15 gastrointestinal stromal tumors. *Science* 279: 577-580, 1998

Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K,
et al: Constitutively activating mutations of *c-kit* receptor
tyrosine kinase confer factor-independent growth and
20 tumorigenicity of factor-dependent hematopoietic cell lines.
Blood 85: 790-798, 1995

Longley BJ, Tyrrell L, Lu S, Ma Y, Langley K, et al: Somatic
c-KIT activating mutation in urticaria pigmentosa and
25 aggressive mastocytosis: establishment of clonality in a
human mast cell neoplasm. *Nature Genet* 12: 312-314, 1996

Longley BJ, Metcalfe DD, Tharp M, Wang X, Tyrrell L, et al:
Activating and dominant inactivating *c-KIT* catalytic domain
30 mutations in distinct clinical forms of human mastocytosis.
Proc Natl Acad Sci USA 96: 1609-1614, 1999

Ma Y, Longley BJ, Wang X, Blount JL, Langley K, Caughey GH:
Clustering of activating mutations in *c-KIT*'s juxtamembrane

- 41 -

coding region in canine mast cell neoplasms. *J Invest Dermatol* 112: 165-170, 1999a

Ma Y, Cunningham ME, Wang X, Ghosh I, Regan L, Longley BJ:
5 Inhibition of spontaneous receptor phosphorylation by residues in a putative α -helix in the KIT intracellular juxtamembrane region. *J Biol Chem* 274: 13399-13402, 1999b

Martin FH, Suggs SV, Langley KE, Lu HS, Ting J, et al:
10 Primary structure and functional expression of rat and human stem cell factor DNAs. *Cell* 63: 203-211, 1990

Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, et al: Identification of a point mutation in the catalytic
15 domain of the protooncogene *c-kit* in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. *Proc Natl Acad Sci USA* 92: 10560-10564, 1995

20 Tsujimura T, Morimoto M, Hashimoto K, Moriyama Y, Kitayama H, et al: Constitutive activation of *c-kit* in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. *Blood* 87: 273-283, 1996

25 Yarden Y, Kuang W-J, Yang-Feng T, Coussens L, Munemitsu S, et al: Human proto-oncogene *c-kit*: a new cell surface receptor tyrosine kinase for an unidentified ligand. *EMBO J* 6: 3341-3351, 1987

30 Third Series of Experiments

Passive Anaphylaxis: SCF and KIT stimulation have a number of effects on mast cells in vitro, but it is not clear what the overall of effects of blocking KIT would be on inflammation and physiology in vivo. For instance, numerous
35 studies have shown that recombinant SCF causes mast cell

- 42 -

activation, directly stimulates mediator release, and alters the threshold for IgE dependent mediator release in vitro (Nakajima et al. Biochem. Biophys. Res. Commun. 1992) (Coleman et al. J. Immunol. 1993) (Columbo et al. 1992) (Bischoff et al. J. Exp. Med. 1992). Furthermore, a single injection of recombinant SCF causes mast cell activation in mice (Werschil et al. J. Exp. Med. 1992). However, daily administration of recombinant SCF to mice results in mast cell hyperplasia which varies at different anatomic sites, but does not result in mast cell activation (Anado et al. J. Clin. Invest. 1993), and the chronic administration of recombinant SCF to mice has variable effects on passive anaphylaxis reactions. Chronic stimulation with recombinant SCF followed by elicitation of passive anaphylaxis results in increased mast cell activation at some anatomic sites but not others and, surprisingly, a decrease in deaths in mice (Anado et al. J. Clin. Invest. 1993). This last result is counter-intuitive and indicates that exact effects of blocking KIT activation in vivo cannot be predicted accurately based on in vitro data. The authors themselves describe the results as unexpected.

To investigate the effects of blocking KIT in vivo, the ACK2 KIT-blocking-antibody and passive cutaneous anaphylaxis were used in the following experiments:

The skin of Balb/c mice was sensitized by an intradermal injection of murine monoclonal IgE specific for dinitrophenyl hapten. A second set of mice was sensitized with both the IgE and ACK2. 24 hours later, dinitrophenylated human serum albumin was injected into the tail veins of the mice in a mixture of 1% Evans' Blue dye (1 mg). Mice were observed for anaphylaxis, and thirty minutes later were sacrificed. The dorsal skin at the area of sensitization was removed for measurement of the amount of extravasated dye. The amount of dye was determined colorometrically after extraction of the skin in 1 ml of 1 Normal KOH overnight, at 37 degrees centigrade. 0.6 Normal phosphoric acid in acetone

- 43 -

(15:13) was added and the mixture cleared by centrifugation. The absorbent intensity (OD) of the supernatant was measured at 620nm spectrophotometrically. The amount of extravasated dye, which is a measure of anaphylaxis, was significantly reduced in the presence of ACK2 (mean OD 0.0223) when compared to animals sensitized without ACK2 (OD 0.0617) a difference which was significant with $p < 0.01$, and the animals treated with ACK2 showed less respiratory distress compared to animals without ACK2.

10

These data demonstrate, for the first time, that blocking the SCF-KIT signaling pathway in vivo can decrease anaphylaxis and bronchospasms. Combined with the data on cutaneous inflammation, they demonstrate that the SCF-KIT pathway is actively involved in inflammatory reactions in vivo, rather than playing merely a supportive role in the development and maintenance of KIT expressing cells. This critical finding shows that acute blockage of the SCF-KIT signaling pathway can inhibit inflammation.

20

Additional Experiments

A KIT blocking antibody was used to determine that SCF-KIT signaling plays an important role in vivo in passive cutaneous anaphylaxis. This suggests that SCF potentiation of IgE receptor signaling is important in vivo. (Figure 13). These are the first in vivo data to suggest that blocking the SCF-KIT signaling pathway would be useful therapeutically for conditions like asthma and allergic rhinitis.

30 References for Third Series of Experiments:

1. Nakajima K, Hirai K, Yamaguchi M, Takaishi T, Ohta K, Morita Y, Ito K. Biochem. Biophys. Res. Commun. 1992, 183:1076-83.
2. Coleman JW, Holliday MR, Kimber I, Zsebo KM and Galli SJ. J. Immunol. 1993, 150: 556-62.

35

- 44 -

3. Columbo M , Horowitz EM, Botana LM, MacGlashan DW Jr., Bochner BS, Gillis S, Zsebo KM, Galli SJ, Lichtenstein LM. J. Immunol. 1992, 149:599-608.
- 5 4. Bischoff SC and Dahinden CA. J. Exp. Med. 1992, 175:237-44.
5. Wershil BK, Tsai M, Geissler EN, Zsebo KM, Galli SJ. J. Exp. Med. 1992, 175:245-55.
- 10 6. Ando A, Martin TR, Galli SJ. J. Clin. Invest. 1993, 92:1639-49.

15

- 45 -

What is claimed:

1. A method of preventing or treating in a subject
5 contact dermatitis which comprises administering to
the subject an amount of a compound capable of
inhibiting the stem cell factor signaling pathway
effective to prevent or treat contact dermatitis so
as to thereby prevent or treat contact dermatitis in
the subject.
- 10 2. A method of preventing or treating in a subject
hyperpigmentation which comprises administering to
the subject an amount of a compound capable of
inhibiting the stem cell factor signaling pathway
15 effective to prevent or treat hyperpigmentation so
as to thereby prevent or treat hyperpigmentation in
the subject.
- 20 3. A method of preventing or treating in a subject
asthma which comprises administering to the subject
an amount of a compound capable of inhibiting the
stem cell factor signaling pathway effective to
prevent or treat asthma so as to thereby prevent or
25 treat asthma in the subject.
4. A method of preventing or treating in a subject
cutaneous inflammation which comprises administering
to the subject an amount of a compound capable of
inhibiting the stem cell factor signaling pathway
30 effective to prevent or treat cutaneous inflammation
so as to thereby prevent or treat cutaneous
inflammation in the subject.
5. A method of preventing or treating in a subject
35 anaphylaxis and bronchospasm which comprises
administering to the subject an amount of a compound
capable of inhibiting the stem cell factor signaling
pathway effective to prevent or treat anaphylaxis

- 46 -

and bronchospasm so as to thereby prevent or treat anaphylaxis and bronchospasm in the subject.

- 5 6. A method of preventing or treating in a subject mastocytosis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat mastocytosis so as to thereby prevent or treat mastocytosis in the
10 subject.
7. A method of preventing or treating in a subject urticaria which comprises administering to the
15 subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat urticaria so as to thereby prevent or treat urticaria in the subject.
8. A method of preventing or treating in a subject
20 hypersensitivity reactions which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat urticaria so as to thereby prevent or treat urticaria in the
25 subject.
9. A method of preventing or treating in a subject
30 airway inflammation which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat airway inflammation so as to thereby prevent or treat airway inflammation in the subject.
- 35 10. The method of claim 9, wherein the airway inflammation is rhinitis.
11. The method of claim 9, wherein the airway

- 47 -

12. A method of preventing or treating in a subject
interstitial cystitis which comprises administering
to the subject an amount of a compound capable of
inhibiting the stem cell factor signaling pathway
effective to prevent or treat interstitial cystitis
so as to thereby prevent or treat interstitial
cystitis in the subject.
13. A method of preventing or treating in a subject a
tumor which expresses activated kit which comprises
administering to the subject an amount of a compound
capable of inhibiting the stem cell factor signaling
pathway effective to prevent or treat a tumor which
expresses activated kit so as to thereby prevent or
treat a tumor which expresses activated kit in the
subject.
14. The method of claim 13, wherein the tumor is a
gastrointestinal stromal tumor.
15. The method of claim 13, wherein the tumor is a germ
cell tumor.
16. The method of any one of claims 1-13, which
comprises inhibiting the kinase enzymatic reaction
of kit protein.
17. The method of any one of claims 1-13, which
comprises inhibiting chymase, elastase or other SCF
cleaving enzymes.
18. The method of any one of claims 1-13, which
comprises inhibiting ligand binding with an
antibody, peptide, or nonpeptide chemical.
19. The method of any one of claims 1-13, which
comprises inhibiting kit dimerization with an
antibody, peptide, or nonpeptide chemical.

- 48 -

20. The method of any one of claims 1-13, wherein downstream signaling of the kit activation pathway is inhibited by blocking substrate association with kit kinase domain.
- 5
21. The method of any one of claims 1-13, wherein downstream signaling of the kit activation pathway is inhibited by blocking enzymatic function in the downstream signaling pathway.
- 10
22. The method of any one of claims 1-13, wherein downstream signaling of the kit activation pathway is inhibited by blocking binding of molecules in the downstream signaling pathway.
- 15
23. The method of any one of claims 1-13, wherein the compound is an antibody or portion thereof.
- 20
24. The method of claim 23, wherein the antibody is a monoclonal antibody.
- 25
25. The method of claim 24, wherein the monoclonal antibody is a human, humanized or a chimeric antibody
26. The method of claim 24, wherein the monoclonal antibody is an anti-kit antibody.
27. The method of claim 26, wherein the anti-kit antibody is ACK2.
- 30
28. The method of any one of claims 1-13, wherein the compound comprises a Fab fragment of an anti-kit antibody.
- 35
29. The method of any one of claims 1-13, wherein the compound comprises the variable domain of an anti-kit antibody.

- 49 -

30. The method of any one of claims 1-13, wherein the compound comprises one or more CDR portions of an anti-kit antibody.
- 5 31. The method of claim 23, wherein the antibody is selected from the group consisting of IgA, IgD, IgE, IgG and IgM.
- 10 32. The method of any one of claims 1-13, wherein the compound comprises a peptide, peptidomimetic, a nucleic acid, or an organic compound with a molecular weight less than 500 Daltons.
- 15 33. The method of any one of claims 1-13, wherein the compound is sSCF, sKIT ligand or a fragment thereof.
34. The method of any one of claims 1-13, wherein the compound is sKIT or a fragment thereof.
- 20 35. The method of any one of claims 1-13, wherein the subject is a mammal.
36. The method of claim 35, wherein the mammal is a human being, dog or cat,
- 25 37. The method of any one of claims 1-13, wherein the administration is intralesional, intraperitoneal, intramuscular, subcutaneous, intravenous, liposome mediated delivery, transmucosal, intestinal, topical, nasal, oral, anal, ocular, otic, intravesicular, or parenteral delivery.
- 30 38. A method of providing contraception to a subject which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent conception so as to thereby provide contraception to the subject.
- 35

- 50 -

39. The method of claim 38, wherein the subject is a male subject.
40. The method of claim 38, wherein the subject is a female subject.
41. The method of claim 38, which comprises inhibiting the kinase enzymatic reaction of kit protein.
42. The method of claim 38, which comprises inhibiting chymase, elastase or other SCF cleaving enzymes.
43. A method of desensitizing a subject to an agent which comprises administering to the subject during the afferent phase of an immune response an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to desensitize the subject to the agent so as to thereby desensitizing the subject to the agent.
44. A method of identifying a composition, a compound, or a procedure which can produce a skin response in a subject, comprising:
- a) administering said composition or compound, or applying said procedure to the transgenic mice which express endogenous epidermal stem cell factor; and
 - b) analyzing the skin of said transgenic mice for response.
45. The method of claim 44, wherein the composition or compound can be administered orally or by injection.
46. The method of claim 44, wherein the composition or compound can be administered topically by contacting the composition or compound with the skin of the transgenic mice.

- 51 -

47. The method of claim 44, wherein the procedure is not previously known.
- 5 48. The procedure identified by the method of claim 44.
49. The method of claim 44, wherein the skin response is inflammation, tanning, melanoma, carcinoma or hyperpigmentation.
- 10 50. The method of claim 44, wherein the composition may be cosmetics, medications or skin care products.
51. The method of claim 44, wherein the composition or
15 compound is not previously known.
52. The composition or compound identified by the method of claim 44.
- 20 53. A mixture for production of a skin response comprising an effective amount of the composition or compound identified by the method of claim 44 and a suitable carrier.
- 25 54. A method of identifying a composition, a compound, or a procedure which can reduce skin response in a subject, comprising:
- 30 a) administering said composition or compound, or applying said procedure to the transgenic mice which express endogenous epidermal stem cell factor and which had been induced to produce a skin disease; and
- 35 b) analyzing the skin of said transgenic mice to determine the reduction of skin response, wherein the reduction of skin response indicates that the composition, compound, or procedure can reduce skin response.

- 52 -

55. The method of claim 54, wherein the composition or compound can be administered orally or by injection.
56. The method of claim 54, wherein the composition or compound can be administered topically by contacting the composition or compound with the skin of the transgenic mice.
57. The method of claim 54, wherein the procedure is not previously known.
58. The procedure identified by the method of claim 54.
59. The method of claim 54, wherein the composition or compound is not previously known.
60. The composition or compound identified by the method of claim 54.
61. A mixture for reducing skin response comprising an effective amount of the composition or compound identified by the method of claim 54 and a suitable carrier.
62. The method of claim 54, wherein the skin response is inflammation, tanning, melanoma, carcinoma or hyperpigmentation.
63. The method of claim 62, wherein the hyperpigmentation is natural occurring hyperpigmentation or post inflammatory hyperpigmentation.
64. The method of claim 62, wherein the inflammation is associated with human hyperpigmentation, or human hypopigmentation.

- 53 -

65. A method of identifying a composition, a compound, or a procedure which can reduce radiation damage to the skin of a subject, comprising:
- 5 a) administering said composition or compound, or applying said procedure to the skin of the transgenic mice which express endogenous epidermal stem cell factor;
- 10 b) subjecting the skin of said transgenic mice and the skin of the control transgenic mice; and
- 15 c) analyzing the effects of said composition, compound, or procedure on reducing skin radiation damages.
66. The method of claim 65, wherein the composition or compound can be administered orally or by injection.
- 20 67. The method of claim 65, wherein the composition or compound can be administered topically by contacting the composition or compound with the skin of the transgenic mice.
- 25 68. The method of claim 65, wherein the procedure is not previously known.
69. The procedure identified by the method of claim 65.
- 30 70. The method of claim 63, wherein the composition or compound is not previously known.
71. The composition or compound identified by the method of claim 65.
- 35 72. A mixture for reducing skin radiation damages comprising an effective amount of the composition or compound identified by the method of claim 65 and a

- 54 -

suitable carrier.

73. The method of claim 65, wherein the radiation is ultra-violet light.
- 5 74. The method of claim 65, wherein the radiation damage is tanning, carcinogenesis, photo-aging, photo-damage or the development of melanoma.
- 10 75. The method of claim 54, wherein the subject is a mouse or a human-being.
76. The method of claim 75, wherein the epidermal stem cell factor transgene encodes either a membrane bound epidermal stem cell factor or a membrane/soluble epidermal stem cell factor.
- 15 77. The method of claim 76, wherein the epidermal stem cell factor transgene encodes a membrane or soluble epidermal stem cell factor.
- 20 78. The method of claim 77, wherein the epidermal stem cell factor transgene is cloned into a construct containing a human cytokeratin 14 promoter.
- 25 79. The method of claim 78, wherein the human cytokeratin 14 promoter causes the expression of the stem cell factor transgene in murine skin of the basal layers of the interadnexal epidermis and the follicular epithelium.
- 30 80. The method of claim 56, wherein the skin response of the transgenic mice can be induced by applying an irritant or an allergic dermatitis inducing agent to said skin.
- 35 81. The method of claim 80, wherein the irritant is croton oil or dinitroflourobenzene.

- 55 -

82. The method of claim 81, wherein the croton oil or
dinotrofluorobenzene are applied to the ear or the
abdominal skin of the transgenic mice; wherein the
abdominal skin is either hairless or shaved.
- 5 83. The method of claim 82, wherein the croton oil is
used at a concentration of 0.2 percent.
84. The method of claim 81, wherein the
10 dinitrofluorobenzene is used at a concentration of
0.5 percent in a 4:1 mixture of acetone and olive
oil.
85. The method of claim 54, wherein the reduction or
15 treatment of hyperpigmentation is determined by
electron microscopic analysis.
86. The method of claim 54, wherein the stem cell factor
inhibitor is a monoclonal antibody.
- 20 87. The method of claim 86, wherein the stem cell factor
inhibitor is a monoclonal antibody.
88. The method of claim 87, wherein the monoclonal
25 antibody is ACK2.
89. A pharmaceutical composition for treating human skin
diseases, comprising (a) a compound that can treat
skin diseases of the transgenic mice which express
30 endogenous epidermal stem cell factor, and (b) a
suitable carrier, wherein the compound specifically
targets the epidermal stem cell factor or its
receptor.
- 35 90. The pharmaceutical composition of claim 89, wherein
the compound is ACK2.

1/13

FIG. 1A





FIG. 1B



2/13

FIG. 2A




FIG. 2B




FIG. 2C





FIG. 2D



FIG. 2E

3/13

FIG. 3A




FIG. 3B





FIG. 3C

4/13

FIG. 4



5/13

FIG. 5A



a

FIG. 5B



c

FIG. 5C

6/13

FIG. 6A




FIG. 6B



FIG. 6C




7/13

FIG. 7A



FIG. 7B



8/13

FIG. 8
ACK2 Effect on DNFB-Induced Ear Swelling
1X Mice 3/16/99




FIG. 9A





FIG. 9B



10/13




FIG. 10

11/13





FIG.11

12/13

ACK2 REDUCES CROTON OIL-INDUCED EAR SWELLING**FIG.12**

13/13




FIG.13

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/12405

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 39/395; C07K 16/00; C12Q 1/70

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/130.1, 143.1, 145.1, 158.1; 435/4; 514/826, 861, 885, 886; 530/388.23, 389.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST, CHEMICAL ABSTRACTS, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	US 5,911,988 A (BROWNELL et al.) 15 June 1999 (15.06.1999), see column 3.	1-90
A, P	US 5,997,865 A (BENNETT et al.) 07 December 1999 (07.12.1999).	1-90
A	US 5,877,396 A (RAVETCH et al.) 02 March 1999 (02.03.1999).	1-90

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

07 JULY 2000

Date of mailing of the international search report

22 AUG 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

RALPH GITOMER

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/12405

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

424/130.1, 143.1, 145.1, 158.1; 435/4; 514/826, 861, 885, 886; 530/388.23, 389.2